This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Lipoprotein Research Stockholm Ab, The Kitasato Institute. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Osman Ahmed: Innovator in PCSK9 Inhibition
Introduction
Osman Ahmed is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). His work is crucial in addressing various health issues related to cholesterol regulation.
Latest Patents
Osman Ahmed holds a patent for a low-molecular weight compound that acts as a PCSK9 inhibitor. This patent, titled "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and pharmaceutical use therefor," describes a compound that inhibits the functions of PCSK9. The patent outlines the use of this compound, along with its pharmaceutically acceptable salts or solvates, in the prevention or treatment of diseases related to PCSK9 functions. He has 1 patent to his name.
Career Highlights
Throughout his career, Osman Ahmed has worked with esteemed organizations such as The Kitasato Institute and Lipoprotein Research Stockholm AB. His experience in these institutions has allowed him to advance his research and contribute to the scientific community effectively.
Collaborations
Due to space constraints, the collaborations section will be omitted.
Conclusion
Osman Ahmed's innovative work in developing PCSK9 inhibitors showcases his dedication to improving health outcomes through pharmaceutical advancements. His contributions are vital in the ongoing fight against cholesterol-related disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile